The Canadian Frailty Network, the Canadian Longitudinal Study of Aging (CLSA), the McMaster Institute for Research on Aging (MIRA) and Metabolon, Inc. are part of a collaborative partnership to develop a $4-million research program. Through the endeavor, Metabolon will leverage its proprietary metabolomics platform to analyze blood samples from Canada’s largest and most comprehensive study on aging. We sat down with Brent Richards, M.D., M.Sc., from the Faculty of Medicine at McGill University, to discuss the Canadian population health collaborative study that is aimed at discovering key frailty biomarkers to shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.